Impetigo Treatment Market Outlook 2030
Impetigo is very common and contagious skin infection disease that generally affects infants and children. This type of infection is caused due to streptococcus or staphylococcus aureus bacteria. Patient who suffer from this infection shows red scores or bump blisters on their faces particularly around their nose, feet, hands, and mouth. This disease is rarely found in adults. People which are in sports activities involving close physical contacts such as wrestling and rugby are susceptible to this disease. Impetigo can be treated with oral drugs such as cephalosporins, penicillin, and tertracycline. Moreover, topical creams help to reduce symptoms of this disease.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the impetigo treatment market.
Top Impacting Factors
- Rise in outbreak of infectious diseases, surge in cases of hospital acquired infections, increase in patient pool suffering from weak immunity disorders, surge in usage of antibiotics across the globes, rise in infant population, and increase in adoption of unhygienic lifestyle in underdeveloped countries are the key factors that drive growth of impetigo treatment market.
- In addition, surge in demand for broad spectrum antibiotics, rise in usage of over the counter medication, increase in healthcare expenditure, continuous mutations of microorganisms leading to new strains of bacteria, surge in mode of transmission of impetigo diseases, and R & D activities to improve quality of drugs for treatment of impetigo are some factors that fuel the growth of impetigo treatment market.
- However, side effects related use of impetigo treatment drugs and presence of alternative generic medication for treatment of impetigo restrain the growth of impetigo treatment market.
- Contrarily, government initiatives for fast track regulatory approvals for novel drugs and growth opportunities in emerging market are expected to offer lucrative opportunities for the expansion of the market.
Market Trends
New Product Launches to Flourish the Market
In 2018, Cutanea Life Sciences announced launch of Xepi Cream, 1%. Xepi cream is a non-fluorinated topical quinolone used in treatment of impetigo in adult and pediatric patients.
In 2018, Medimetriks Pharmaceutical announced launch of novel topical Ozenoxacin cream. This cream recent got approval from Food and Drug Administration and can be used in treatment of impetigo.
Key Benefits of the Report
- This study presents the analytical depiction of impetigo treatment market industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the impetigo treatment market share.
- The current market is quantitatively analyzed to highlight the impetigo treatment market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Impetigo Treatment Market Report
- Which are the leading players active in the impetigo treatment market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is "impetigo treatment"?
- What is "impetigo treatment" market prediction in the future?
- Who are the leading global players in the "impetigo treatment" market?
- What are the current trends and predicted trends?
- What are the key benefits of the "impetigo treatment" market report?
Impetigo Treatment Market Report Highlights
| Aspects | Details |
 By Drug Class |
|
 By Route of Administration |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Taro Pharmaceutical Industries Ltd, Ranbaxy Laboratories Limited, Roche Holding AG, Karalex Pharma, LLC, Pfizer, Inc., Teva Pharmaceutical Industries Ltd, NovaBay Pharmaceuticals, Inc., GlaxoSmithKline plc, Lupin Limited, Leo Pharma A/S, SANDOZ GmbH |
Loading Table Of Content...
